Responses
Endometrial cancer
2022-RA-712-ESGO Real-world prevalence of microsatellite instability testing and related status in patients with recurrent or advanced endometrial cancer initiating first line of therapy in Europe
Compose a Response to This Article
Other responses
No responses have been published for this article.